Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vacc

Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vacc

Item

http://www.wikidata.org/entity/Q33613482

Q33613482

about

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity Global practices of meningococcal vaccine use and impact on invasive disease.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age.Meningococcal glycoconjugate vaccines.Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.Meningococcal conjugate vaccines: optimizing global impact.Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.Human Infant Memory B Cell and CD4+ T Cell Responses to HibMenCY-TT Glyco-Conjugate Vaccine.Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?Patterns of binding of aluminum-containing adjuvants to Haemophilus influenzae type b and meningococcal group C conjugate vaccines and components Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.Persistence of influenza vaccine-induced antibody in lung transplant patients and healthy individuals beyond the season.Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Con Vaccine development against Neisseria meningitidis.New frontiers in meningococcal vaccines.Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.Bexsero: a multicomponent vaccine for prevention of meningococcal disease.Advances with vaccination against Neisseria meningitidis.Glycoconjugate vaccines.Evolving meningococcal immunization strategies.Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.A model for the regulation of follicular dendritic cells predicts invariant reciprocal-time decay of post-vaccine antibody response.What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK Experience.Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response.Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study.

P2860

Q28650557-0BA72483-338A-4A82-9CC4-393D2D7814C1 Q28749695-D5EAE137-99D1-4091-B8E4-399A8D5C1584 Q33806774-2D29391C-77FC-45F9-93B9-1EB7FEBECED3 Q33825722-D08D1070-66CA-41DC-B18C-A7B317701258 Q33850840-72B52578-249C-4470-99DC-BAE9B01CB386 Q34170021-9B9ABE7E-1173-4273-951E-6F09321CAE26 Q34721179-D2FEC629-3845-4B2A-8D8E-B06F9FE71BE9 Q34739082-82E64FE6-E621-40D7-84E7-59DBE28BE303 Q35194824-9412346D-25CC-4A64-AA7D-7249D6508B6F Q35198778-E5721BEA-A4EF-4A9E-9D87-CE65878003F5 Q35547767-729E4E13-F679-44D2-9E67-94F9197D3737 Q35598188-7A76F553-BE6D-44D6-9A20-236C59A0D3CD Q35697891-AC6ACA8F-FC23-4923-911E-42A69CABD47F Q35887266-CD629A93-C1B4-4BBC-8CE4-81FEA5BFAFDF Q36090625-5516039F-DE59-416A-9057-14A9D7A6F705 Q36154716-DE3766BA-A0AF-4734-809D-5D4A275FC1C1 Q36265103-45B691E4-2918-437D-B3DC-DE83EA62EBD0 Q36391874-3C43F368-475D-4D41-802C-8440D07EEB4E Q36849805-79D8BD42-803D-4EAD-A757-71DB94A523D7 Q36849834-B47A7C19-798B-4196-ABD0-D0BDD42746F6 Q37067275-1B993B99-5BB6-4C22-B1A9-C69D47DCBD6F Q37274707-528A8E06-FB28-45CA-85A7-5CE64ED2F6B5 Q37878480-DD8DF0D7-FB68-4CC3-AB77-D3CEBF4C94A4 Q37878485-05C83E3F-A8E7-4CB5-9F3E-A34804A30528 Q37994540-7313579E-ACC6-4304-8E06-017F193F6699 Q38040527-C8A201BB-A59E-4F9F-BEBA-AF17705F6CE1 Q38044755-D96269E1-2B00-4731-8A71-299AA625E076 Q38286082-4BD0B2E3-E069-4196-BDEF-DD57914E3DED Q38367830-F3807901-D0DA-4008-9A87-171BE1081115 Q38631381-8E5DF928-CF8F-497F-A3ED-6D9453626A21 Q39447300-225333F6-8C4A-48F0-88C5-447842E57F78 Q40778094-5E1B4D5A-0172-4371-8840-6D74B7C6A0E5 Q41812746-1C5E7E6B-0EC0-4D87-8E82-6C28E8EBD736 Q42255158-DC9EF8A4-009E-48E1-A30E-C2613AB9027A Q42270579-B2D0E793-915D-4774-A320-0349E9101BF4

P2860

Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vacc

Item

http://www.wikidata.org/entity/Q33613482

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue